Vasculitis & polymyalgia rheumatica
Rituximab resistance at 3 months of induction therapy in newly diagnosed or relapsing antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis: A French multicentre retrospective study in 116 patients
Authors' conclusion
Twelve percent of patients had RTX resistance at M3. These patients more often had localized form of the disease and were less treated by initial MP pulse and by prophylactic trimethoprim-sulfamethoxazole.
Study context
- Population
- Patients with newly diagnosed or relapsing AAV (GPA or MPA) receiving rituximab (RTX) induction therapy, France, 2010–2020116 analysed
- Participants
- 121 patients
- Exposure
- RTX resistance at M3 vs responders
- RTX resistancen = 14
- Outcome
- RTX resistance: uncontrolled disease (worsening feature on BVAS/WG 1 month after RTX induction) or disease flare (increase in BVAS/WG ≥1 point before M3)
- Follow-up
- 3 months (M3)
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
RTX resistance at M3
RTX resistance
12%
14
Observational data: associations, not effects.
Further findings
Localized disease
P < 0.05
Initial methylprednisolone pulse
P < 0.01
Prophylactic trimethoprim-sulfamethoxazole
P < 0.05
- Additional immunosuppressive therapy in RTX resistance
- 7 · events
Remission · 6 months
- All patients were in remission at 6 months
Deaths during follow-up
- Deaths
- 24
- Due to infections
- one-third
- Due to SARS-CoV-2
- half
Original publication
Rituximab resistance at 3 months of induction therapy in newly diagnosed or relapsing ANCA-associated vasculitis: A French multicentre retrospective study in 116 patients. Joint Bone Spine. Published 23 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →